Leukocare Raises USD 17.5M in Financing
Summary
Leukocare AG, a Martinsried/Munich, Germany and Milford, MA, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m (€14.6m) financing. Following the financing, Tadd Wessel, Founder and Managing Partner at Petrichor, will join Leukocare’s Supervisory Board. Led by Michael Scholl, Chief Executive Officer, Leukocare is a biotechnology company specialized in the field of biopharmaceutical formulation development. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product’s needs. Leukocare’s drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.